Get the Stockscreener App
119.72
10.40%
-13.89
After Hours:
119.73
0.01
+0.01%
Illumina Inc stock is traded at $119.72, with a volume of 4.45M.
It is down -10.40% in the last 24 hours and down -18.62% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$133.61
Open:
$125.99
24h Volume:
4.45M
Relative Volume:
2.38
Market Cap:
$18.29B
Revenue:
$4.29B
Net Income/Loss:
$703.00M
P/E Ratio:
26.82
EPS:
4.4635
Net Cash Flow:
$993.00M
1W Performance:
-17.33%
1M Performance:
-18.62%
6M Performance:
+26.78%
1Y Performance:
-2.51%
1-Day Range:
$117.67
$128.16
1-Week Range:
$117.67
$143.56
52-Week Range:
$68.70
$155.53
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
119.72 | 20.42B | 4.29B | 703.00M | 993.00M | 4.4635 |
|
TMO
Thermo Fisher Scientific Inc
|
542.83 | 203.77B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
216.61 | 152.51B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
644.61 | 51.39B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
129.58 | 36.75B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
187.49 | 30.69B | 15.90B | 1.28B | 2.21B | 7.2842 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Illumina, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - 富途牛牛
Is Illumina’s (ILMN) Clinical Consumables Surge Quietly Redefining Its Core Investment Story? - Yahoo Finance UK
Analysts Conflicted on These Healthcare Names: Illumina (ILMN) and Ocular Therapeutix (OCUL) - The Globe and Mail
Could Nvidia Be the Best Way to Play the AI Boom in 2026? - The Motley Fool
Illumina (ILMN) stock slides 10% after 2026 outlook puts China, research demand back in focus - TechStock²
Illumina, Inc.'s (NASDAQ:ILMN) Business Is Yet to Catch Up With Its Share Price - 富途牛牛
Illumina Enters Oversold Territory (ILMN) - Nasdaq
UBS Adjusts Illumina Price Target to $135 From $120, Maintains Neutral Rating - marketscreener.com
Molina Healthcare, Coty, Illumina, Amazon and other big stocks moving lower in Friday's pre-market session - MSN
Illumina, Inc. (NASDAQ:ILMN) Q4 2025 Earnings Call Transcript - Insider Monkey
Illumina revenue up 5% to USD 1.16B in Q4 2025 - Medical Buyer
ILMN Q4 Deep Dive: Clinical Consumables Growth, Multiomics Expansion, and Margin Momentum - Yahoo Finance
Illumina Q4 2025 slides: Clinical growth accelerates as NovaSeq X transition advances By Investing.com - Investing.com South Africa
Illumina Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Illumina beats Q4 2025 EPS forecast by 10.66% - Investing.com Canada
Illumina (ILMN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Illumina Q4 2025 slides: Clinical growth accelerates as NovaSeq X transition advances - Investing.com
Illumina Inc (NASDAQ:ILMN) Stock Falls Despite Q4 Earnings Beat on Cautious 2026 Outlook - Chartmill
Illumina (ILMN) Tops Q4 Earnings and Revenue Estimates - Nasdaq
Illumina: Q4 Earnings Snapshot - kens5.com
Illumina shares tumble as flat revenue disappoints investors By Investing.com - Investing.com South Africa
Illumina Inc. Q4 Profit Advances - Nasdaq
Illumina Q4 Non-GAAP Earnings, Revenue Rise; 2026 Outlook Set - marketscreener.com
Illumina (NASDAQ:ILMN) Reports Bullish Q4 CY2025 - TradingView
Illumina Q4 Earnings Summary & Key Takeaways - Benzinga
Earnings Flash (ILMN) Illumina, Inc. Reports Q4 Revenue $1.16B, vs. FactSet Est of $1.12B - marketscreener.com
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025 - PR Newswire
Illumina earnings loom as investors seek clarity on 2026 outlook By Investing.com - au.investing.com
Insights Into Illumina (ILMN) Q4: Wall Street Projections for Key Metrics - Yahoo Finance
Multi-Omics Market Set for Explosive Growth to USD 33.25 Billion - openPR.com
San Diego Zoo’s Frozen Zoo Gets Genomic Boost - 101.5 KGB
Synthetic Biology Market Set for Explosive Growth to USD 67.47 - openPR.com
Mediolanum International Funds Ltd Makes New $914,000 Investment in Illumina, Inc. $ILMN - MarketBeat
Illumina (ILMN) Reports Q4: Everything You Need To Know Ahead Of Earnings - Finviz
What Catalysts Are Shifting The Illumina (ILMN) Story For 2026 And Beyond - Yahoo Finance
Illumina, Inc. and the San Diego Zoo Wildlife Alliance Partner to Sequence the Frozen Zoo - marketscreener.com
Illumina Partners with San Diego Zoo for Genomic Sequencing of Endangered Species - intellectia.ai
Press Release - Illumina
Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globally - PR Newswire
WCM Investment Management LLC Has $384.17 Million Position in Illumina, Inc. $ILMN - MarketBeat
Bioinformatics Market to Witness Massive Growth by 2033: - openPR.com
Mapping the future of whole-genome sequencing with Illumina constellation technology - Illumina
Video: UK Festival of Genomics & Biodata 2026 - Illumina
PacBio sells short-read DNA sequencing assets to Illumina for $48.1m - Investing.com Canada
Pacific Biosciences of California Closes $48.1 Million Sale of DNA Sequencing Assets to Illumina - marketscreener.com
PacBio (PACB) Finalizes Asset Sale to Illumina, Secures $48.1 Mi - GuruFocus
Illumina completes acquisition of SomaLogic - marketscreener.com
Illumina buys SomaLogic in bid to expand proteomics reach - The Pharma Letter
ILMN Q4 Earnings Preview: NovaSeq X Momentum Likely to Aid Performance - TradingView
Pacific Biosciences of California Signs Asset Purchase Agreement With Illumina Cambridge - TradingView
Does CMS Backing of TruSight Oncology Recast Illumina’s (ILMN) Clinical Genomics Potential? - simplywall.st
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.83%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):